Project Grant HT94252410231
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This $1,539,818.00 Department of the Army Medical Command federal Project Grant award under the Military Medical Research and Development program (CFDA 12.420) will fund research led by the Regents of the University of Minnesota to develop multiplex edited, dual CAR gamma delta T cells targeting pediatric solid tumors. The three-year project, with a performance period from November 15, 2024 to November 14, 2027, seeks to advance innovative cell-based immunotherapies for the treatment of...
This Project Grant award of $154,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Regents of the University of Minnesota to develop a dual-targeting G/D CAR-T cell therapy for the treatment of rhabdomyosarcoma. The award period runs from September 1, 2025 to August 31, 2027. The University of Minnesota, a prominent land-grant research institution, will leverage its extensive medical research capabilities to...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,155,000 Project Grant to the Regents of the University of Minnesota to evaluate prostate cancer patient natural killer cell function across racial backgrounds and address functional disparities with trispecific killer engagers. The award, which runs from June 1, 2025 to May 31, 2029, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans,...
This federal Project Grant award of $614,150.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the Regents of the University of Minnesota to enhance the long-term persistence of Chimeric Antigen Receptor (CAR)-Natural Killer (NK) cells for treating solid tumors. The award period runs from July 1, 2025 to June 30, 2027. As a prominent land-grant research institution, the University of Minnesota has a strong track record of...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,618,500.00 to the Regents of the University of Minnesota to support research aimed at "Targeting eIF4F Complex-Driven Translation of Oncogenic mRNAs in CRPC". The 3-year award, which runs from June 1, 2025 to May 31, 2028, will fund advanced biomedical research focused on innovative solutions to transform healthcare for military service...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,848,000.00 to the Regents of the University of Minnesota to conduct research on therapeutic targeting of aberrant mRNA polyadenylation in lethal prostate cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations in this critical medical domain. The...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $1,348,041.00 to the Regents of the University of Minnesota to develop a RET-specific proteomic assay from circulating tumor cells in lethal prostate cancer. The award began on Mar 1, 2024 and is scheduled for completion by Feb 28, 2027. This research aims to transform health care for military service members and the general public through innovative...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $787,793 Project Grant to the Regents of the University of Minnesota to conduct research on "LEVERAGING TARGETED BIOLOGICAL COMPLEXES TO MAXIMIZE NATURAL KILLER CELL IMMUNOTHERAPY IN LUNG CANCER". The three-year award, running from July 1, 2024 to June 30, 2027, will support the university's efforts to develop innovative immunotherapy approaches for treating lung cancer, with a...